Entry - #619132 - FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 8; FTDALS8 - OMIM
# 619132

FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 8; FTDALS8


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
16q12.1 ?Frontotemporal dementia and/or amyotrophic lateral sclerosis 8 619132 AD 3 CYLD 605018
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE
- Autosomal dominant
ABDOMEN
Gastrointestinal
- Dysphagia
MUSCLE, SOFT TISSUES
- Muscle wasting
- Muscle weakness due to neurodegeneration
NEUROLOGIC
Central Nervous System
- Frontotemporal dementia
- Memory impairment
- Executive dysfunction
- Amyotrophic lateral sclerosis (in some patients)
- Fasciculations
- Upper and lower motor neuron disease
- Frontotemporal atrophy
- Neuropathologic studies show tau-immunoreactive inclusions
- TDP43-immunoreactive inclusions
Behavioral Psychiatric Manifestations
- Personality changes
- Behavioral abnormalities
MISCELLANEOUS
- Adult onset
- Progressive disorder
- Variable phenotype
- Some patients have either FTD or ALS
- Some patients have both FTD and ALS
- One family has been reported (last curated December 2020)
MOLECULAR BASIS
- Caused by mutation in the CYLD lysine-63 deubiquitinase gene (CYLD, 605018.0012)
Amyotrophic lateral sclerosis - PS105400 - 40 Entries
Location Phenotype Inheritance Phenotype
mapping key
Phenotype
MIM number
Gene/Locus Gene/Locus
MIM number
1p36.22 Amyotrophic lateral sclerosis 10, with or without FTD AD 3 612069 TARDBP 605078
1p36.22 Frontotemporal lobar degeneration, TARDBP-related AD 3 612069 TARDBP 605078
2p13.3 Amyotrophic lateral sclerosis 26 with or without frontotemporal dementia AD 3 619133 TIA1 603518
2p13.1 {Amyotrophic lateral sclerosis, susceptibility to} AD, AR 3 105400 DCTN1 601143
2q33.1 Amyotrophic lateral sclerosis 2, juvenile AR 3 205100 ALS2 606352
2q34 Amyotrophic lateral sclerosis 19 AD 3 615515 ERBB4 600543
2q35 Amyotrophic lateral sclerosis 22 with or without frontotemporal dementia AD 3 616208 TUBA4A 191110
3p11.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 AD 3 600795 CHMP2B 609512
4q33 {Amyotrophic lateral sclerosis, susceptibility to, 24} AD 3 617892 NEK1 604588
5q31.2 Amyotrophic lateral sclerosis 21 AD 3 606070 MATR3 164015
5q35.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 3 AD 3 616437 SQSTM1 601530
6q21 Amyotrophic lateral sclerosis 11 AD 3 612577 FIG4 609390
8q22.3 Amyotrophic lateral sclerosis 28 AD 3 620452 LRP12 618299
9p21.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 1 AD 3 105550 C9orf72 614260
9p13.3 ?Amyotrophic lateral sclerosis 16, juvenile AR 3 614373 SIGMAR1 601978
9p13.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 6 AD 3 613954 VCP 601023
9q22.31 Amyotrophic lateral sclerosis 27, juvenile AD 3 620285 SPTLC1 605712
9q34.13 Amyotrophic lateral sclerosis 4, juvenile AD 3 602433 SETX 608465
10p13 Amyotrophic lateral sclerosis 12 with or without frontotemporal dementia AD, AR 3 613435 OPTN 602432
10q22.3 Amyotrophic lateral sclerosis 23 AD 3 617839 ANXA11 602572
12q13.12 {Amyotrophic lateral sclerosis, susceptibility to} AD, AR 3 105400 PRPH 170710
12q13.13 Amyotrophic lateral sclerosis 20 AD 3 615426 HNRNPA1 164017
12q13.3 {Amyotrophic lateral sclerosis, susceptibility to, 25} AD 3 617921 KIF5A 602821
12q14.2 Frontotemporal dementia and/or amyotrophic lateral sclerosis 4 AD 3 616439 TBK1 604834
12q24.12 Spinocerebellar ataxia 2 AD 3 183090 ATXN2 601517
12q24.12 {Amyotrophic lateral sclerosis, susceptibility to, 13} AD 3 183090 ATXN2 601517
14q11.2 Amyotrophic lateral sclerosis 9 3 611895 ANG 105850
15q21.1 Amyotrophic lateral sclerosis 5, juvenile AR 3 602099 SPG11 610844
16p13.3 Frontotemporal dementia and/or amyotrophic lateral sclerosis 5 AD 3 619141 CCNF 600227
16p11.2 Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia 3 608030 FUS 137070
16q12.1 ?Frontotemporal dementia and/or amyotrophic lateral sclerosis 8 AD 3 619132 CYLD 605018
17p13.2 Amyotrophic lateral sclerosis 18 3 614808 PFN1 176610
18q21 Amyotrophic lateral sclerosis 3 AD 2 606640 ALS3 606640
20p13 Amyotrophic lateral sclerosis 7 2 608031 ALS7 608031
20q13.32 Amyotrophic lateral sclerosis 8 AD 3 608627 VAPBC 605704
21q22.11 Amyotrophic lateral sclerosis 1 AD, AR 3 105400 SOD1 147450
22q11.23 Frontotemporal dementia and/or amyotrophic lateral sclerosis 2 AD 3 615911 CHCHD10 615903
22q12.2 {?Amyotrophic lateral sclerosis, susceptibility to} AD, AR 3 105400 NEFH 162230
Xp11.21 Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia XLD 3 300857 UBQLN2 300264
Not Mapped Amyotrophic lateral sclerosis, juvenile, with dementia AR 205200 ALSDC 205200
Frontotemporal dementia and/or amyotrophic lateral sclerosis - PS105550 - 8 Entries

TEXT

A number sign (#) is used with this entry because of evidence that frontotemporal dementia and/or amyotrophic lateral sclerosis-8 (FTDALS8) is caused by heterozygous mutation in the CYLD gene (605018) on chromosome 16q12. One such family has been reported.


Description

Frontotemporal dementia and/or amyotrophic lateral sclerosis-8 (FTDALS8) is an autosomal dominant neurodegenerative disorder characterized by adult-onset dementia manifest as memory impairment, executive dysfunction, and behavioral or personality changes. Some patients may develop ALS or parkinsonism. Neuropathologic studies show frontotemporal lobar degeneration (FTLD) with tau (MAPT; 157140)- and TDP43 (605078)-immunoreactive inclusions (summary by Dobson-Stone et al., 2020).

For a discussion of genetic heterogeneity of FTDALS, see FTDALS1 (105550).


Clinical Features

Dobson-Stone et al. (2013) reported a large multigenerational kindred of European Australian descent (Aus-12) in which at least 10 individuals spanning 4 generations had a similar neurodegenerative disorder. The family was subsequently reported by Dobson-Stone et al. (2020). Most patients had FTD; 1 had FTD and ALS, and 3 had ALS without dementia. All patients were deceased at the time of the report. Clinical details were provided for some of the patients. The proband presented at 56 years of age with memory deficits and personality changes. Her features were initially consistent with Alzheimer disease (AD; 104300), but progression of the disorder and frontotemporal hypoperfusion on imaging led to a diagnosis of FTD. She died at age 68. Another family member showed progressively abnormal behavior in his fifties and died at age 64. Two more family members had features of adult-onset ALS with fasciculations and active limb denervation. One of these patients with ALS also had FTD, Paget disease, and parkinsonism, whereas the other had severe ALS with paralysis, dysarthria, dysphagia, and muscle wasting, but no apparent dementia. Neuropathologic examination of 2 patients showed frontotemporal atrophy with neuronal and glial accumulation of phospho-tau, as well as TDP43-positive neuronal cytoplasmic inclusions. The pathologic diagnosis was FTLD-TDP type B.


Inheritance

The transmission pattern of FTDALS8 in the family reported by Dobson-Stone et al. (2020) was consistent with autosomal dominant inheritance.


Molecular Genetics

In 5 affected individuals from a large multigenerational family of European Australian descent (Aus-12) with FTDALS8, Dobson-Stone et al. (2013) and Dobson-Stone et al. (2020) identified a heterozygous missense mutation in the CYLD gene (M719V; 605018.0012). Mutations in the FUS gene (137070) were excluded. The CYLD mutation, which was found by a combination of linkage analysis and whole-exome sequencing, segregated with the disorder in the family. It was not present in several public databases, including gnomAD. Transfection of primary mouse cortical neurons with mutant M719V CYLD resulted in an increased proportion of neurons with cytoplasmic TDP43 (605078) staining (55%) compared to cells transfected with wildtype CYLD (34%). The mutation also altered axonal morphology, leading to a decrease in axonal length. Additional in vitro cellular studies showed that the M719V mutation resulted in increased K63 deubiquitinase activity, enhanced inhibition of NFKB, and impaired autophagosome fusion with lysosomes compared to wildtype, indicating a gain-of-function effect. The authors noted that other disorders associated the CYLD mutations result in a loss of function. CYLD was found to directly interact with TBK1 (604834), OPTN (602432), and SQSTM1 (601530), all of which are implicated in autophagy and, when mutated, are causative of FTD or ALS. Neuropathologic analysis of postmortem brain tissue of 2 affected individuals showed widespread glial CYLD immunoreactivity that was not present in other patients with sporadic FTD. There were also patchy areas of diffuse neuronal cytoplasmic CYLD staining in the hippocampus and frontal cortex, as well as CYLD immunoreactivity in the nuclei of pyknotic neurons. CYLD did not colocalize with either tau or TDP43 inclusions. The report thus identified another molecular mechanism by which impaired autophagy can result in a neurodegenerative disorder. CYLD mutations were not found in several cohorts of ALS and FTD patients comprising several thousand individuals, suggesting that it is a rare cause of the disorder.

In 2 of 65 Portuguese patients with FTD who underwent whole-exome sequencing, Tabuas-Pereira et al. (2020) identified heterozygous missense variants in the CYLD gene (S615F and P229S). Both variants had low frequencies in the gnomAD database (less than 9 x 10(-6)); functional studies of the variants were not performed and family members were not available for segregation studies. The patients had onset of progressive dementia with executive dysfunction and memory impairment at 53 and 74 years of age, respectively. The phenotype was reminiscent of Alzheimer disease.


REFERENCES

  1. Dobson-Stone, C., Hallupp, M., Shahheydari, H., Ragagnin, A. M. G., Chatterton, Z., Carew-Jones, F., Shepherd, C. E., Stefen, H., Paric, E., Fath, T., Thompson, E. M., Blumbergs, P., and 28 others. CYLD is a causative gene for frontotemporal dementia-amyotrophic lateral sclerosis. Brain 143: 783-799, 2020. [PubMed: 32185393, related citations] [Full Text]

  2. Dobson-Stone, C., Luty, A. A., Thompson, E. M., Blumbergs, P., Brooks, W. S., Short, C. L., Field, C. D., Panegyres, P. K., Hecker, J., Solski, J. A., Blair, I. P., Fullerton, J. M., Halliday, G. M., Schofield, P. R., Kwok, J. B. J. Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. Acta Neuropath. 125: 523-533, 2013. [PubMed: 23338750, related citations] [Full Text]

  3. Tabuas-Pereira, M., Santana, I., Kun-Rodrigues, C., Bras, J., Guerreiro, R. CYLD variants in frontotemporal dementia associated with severe memory impairment in a Portuguese cohort. (Letter) Brain 143: e67, 2020. [PubMed: 32666117, related citations] [Full Text]


Creation Date:
Cassandra L. Kniffin : 12/21/2020
carol : 01/06/2021
ckniffin : 12/30/2020

# 619132

FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 8; FTDALS8


ORPHA: 275864;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
16q12.1 ?Frontotemporal dementia and/or amyotrophic lateral sclerosis 8 619132 Autosomal dominant 3 CYLD 605018

TEXT

A number sign (#) is used with this entry because of evidence that frontotemporal dementia and/or amyotrophic lateral sclerosis-8 (FTDALS8) is caused by heterozygous mutation in the CYLD gene (605018) on chromosome 16q12. One such family has been reported.


Description

Frontotemporal dementia and/or amyotrophic lateral sclerosis-8 (FTDALS8) is an autosomal dominant neurodegenerative disorder characterized by adult-onset dementia manifest as memory impairment, executive dysfunction, and behavioral or personality changes. Some patients may develop ALS or parkinsonism. Neuropathologic studies show frontotemporal lobar degeneration (FTLD) with tau (MAPT; 157140)- and TDP43 (605078)-immunoreactive inclusions (summary by Dobson-Stone et al., 2020).

For a discussion of genetic heterogeneity of FTDALS, see FTDALS1 (105550).


Clinical Features

Dobson-Stone et al. (2013) reported a large multigenerational kindred of European Australian descent (Aus-12) in which at least 10 individuals spanning 4 generations had a similar neurodegenerative disorder. The family was subsequently reported by Dobson-Stone et al. (2020). Most patients had FTD; 1 had FTD and ALS, and 3 had ALS without dementia. All patients were deceased at the time of the report. Clinical details were provided for some of the patients. The proband presented at 56 years of age with memory deficits and personality changes. Her features were initially consistent with Alzheimer disease (AD; 104300), but progression of the disorder and frontotemporal hypoperfusion on imaging led to a diagnosis of FTD. She died at age 68. Another family member showed progressively abnormal behavior in his fifties and died at age 64. Two more family members had features of adult-onset ALS with fasciculations and active limb denervation. One of these patients with ALS also had FTD, Paget disease, and parkinsonism, whereas the other had severe ALS with paralysis, dysarthria, dysphagia, and muscle wasting, but no apparent dementia. Neuropathologic examination of 2 patients showed frontotemporal atrophy with neuronal and glial accumulation of phospho-tau, as well as TDP43-positive neuronal cytoplasmic inclusions. The pathologic diagnosis was FTLD-TDP type B.


Inheritance

The transmission pattern of FTDALS8 in the family reported by Dobson-Stone et al. (2020) was consistent with autosomal dominant inheritance.


Molecular Genetics

In 5 affected individuals from a large multigenerational family of European Australian descent (Aus-12) with FTDALS8, Dobson-Stone et al. (2013) and Dobson-Stone et al. (2020) identified a heterozygous missense mutation in the CYLD gene (M719V; 605018.0012). Mutations in the FUS gene (137070) were excluded. The CYLD mutation, which was found by a combination of linkage analysis and whole-exome sequencing, segregated with the disorder in the family. It was not present in several public databases, including gnomAD. Transfection of primary mouse cortical neurons with mutant M719V CYLD resulted in an increased proportion of neurons with cytoplasmic TDP43 (605078) staining (55%) compared to cells transfected with wildtype CYLD (34%). The mutation also altered axonal morphology, leading to a decrease in axonal length. Additional in vitro cellular studies showed that the M719V mutation resulted in increased K63 deubiquitinase activity, enhanced inhibition of NFKB, and impaired autophagosome fusion with lysosomes compared to wildtype, indicating a gain-of-function effect. The authors noted that other disorders associated the CYLD mutations result in a loss of function. CYLD was found to directly interact with TBK1 (604834), OPTN (602432), and SQSTM1 (601530), all of which are implicated in autophagy and, when mutated, are causative of FTD or ALS. Neuropathologic analysis of postmortem brain tissue of 2 affected individuals showed widespread glial CYLD immunoreactivity that was not present in other patients with sporadic FTD. There were also patchy areas of diffuse neuronal cytoplasmic CYLD staining in the hippocampus and frontal cortex, as well as CYLD immunoreactivity in the nuclei of pyknotic neurons. CYLD did not colocalize with either tau or TDP43 inclusions. The report thus identified another molecular mechanism by which impaired autophagy can result in a neurodegenerative disorder. CYLD mutations were not found in several cohorts of ALS and FTD patients comprising several thousand individuals, suggesting that it is a rare cause of the disorder.

In 2 of 65 Portuguese patients with FTD who underwent whole-exome sequencing, Tabuas-Pereira et al. (2020) identified heterozygous missense variants in the CYLD gene (S615F and P229S). Both variants had low frequencies in the gnomAD database (less than 9 x 10(-6)); functional studies of the variants were not performed and family members were not available for segregation studies. The patients had onset of progressive dementia with executive dysfunction and memory impairment at 53 and 74 years of age, respectively. The phenotype was reminiscent of Alzheimer disease.


REFERENCES

  1. Dobson-Stone, C., Hallupp, M., Shahheydari, H., Ragagnin, A. M. G., Chatterton, Z., Carew-Jones, F., Shepherd, C. E., Stefen, H., Paric, E., Fath, T., Thompson, E. M., Blumbergs, P., and 28 others. CYLD is a causative gene for frontotemporal dementia-amyotrophic lateral sclerosis. Brain 143: 783-799, 2020. [PubMed: 32185393] [Full Text: https://doi.org/10.1093/brain/awaa039]

  2. Dobson-Stone, C., Luty, A. A., Thompson, E. M., Blumbergs, P., Brooks, W. S., Short, C. L., Field, C. D., Panegyres, P. K., Hecker, J., Solski, J. A., Blair, I. P., Fullerton, J. M., Halliday, G. M., Schofield, P. R., Kwok, J. B. J. Frontotemporal dementia-amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. Acta Neuropath. 125: 523-533, 2013. [PubMed: 23338750] [Full Text: https://doi.org/10.1007/s00401-013-1078-9]

  3. Tabuas-Pereira, M., Santana, I., Kun-Rodrigues, C., Bras, J., Guerreiro, R. CYLD variants in frontotemporal dementia associated with severe memory impairment in a Portuguese cohort. (Letter) Brain 143: e67, 2020. [PubMed: 32666117] [Full Text: https://doi.org/10.1093/brain/awaa183]


Creation Date:
Cassandra L. Kniffin : 12/21/2020

Edit History:
carol : 01/06/2021
ckniffin : 12/30/2020